Search results for " Weekly chemotherapy"

showing 2 items of 2 documents

Weekly Dose-Dense Cisplatin-Epirubicin-Paclitaxel Administration with Granulocyte Colony-Stimulating Factor Support Does Not Substantially Improve Pr…

2004

Purpose: The present study was aimed at defining the antitumor activity of the cisplatin-epirubicin-paclitaxel (PET) weekly administration with granulocyte colony-stimulating factor (G-CSF) support in chemonaive small-cell lung cancer patients with extensive disease (ED-SCLC). Methods: Chemonaive ED-SCLC patients received cisplatin 30 mg/sqm, epirubicin 50 mg/sqm and paclitaxel 120 mg/sqm, weekly, with G-CSF (5 μg/kg from day 3 to 5) support, for a maximum of 12 weeks. Results: Thirty-nine patients were treated, for a total of 354 cycles delivered. Eight complete (21%), and 22 partial responses (56%) were recorded, giving a 77% (95% Cl = 61-89%) objective response rate (ORR). After 14 (rang…

AdultMaleLung NeoplasmsPaclitaxelMiddle AgedPrognosisSmall-cell lung cancer Weekly chemotherapy Paclitaxel Epirubicin CisplatinSurvival AnalysisDrug Administration ScheduleTreatment OutcomeAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactorHumansFemaleCarcinoma Small CellCisplatinInfusions IntravenousAgedEpirubicin
researchProduct

Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of …

2006

Abstract Background Elderly patients have been often excluded from or underrepresented in the study populations of combination chemotherapy trials. The primary end point of this study was to determine the response rate and the toxicity of the weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) regimen in elderly patients with advanced gastric cancer. The secondary objective was to measure the time to disease progression and the survival time. Methods Chemotherapy-naive patients with advanced gastric cancer aged 70 or older were considered eligible for study entry. Patients received weekly oxaliplatin 40 mg/m2, fluorouracil 500 mg/m2 and folinic acid 250 mg/m2. All drugs were given i…

MaleOncologymedicine.medical_specialtyCancer ResearchOrganoplatinum Compoundsmedicine.medical_treatmentlcsh:RC254-282Drug Administration ScheduleLEUCOVORINFolinic acidEPI-DOXORUBICINTRACT CANCERCISPLATINADVANCED ESOPHAGOGASTRIC CANCERStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointGeneticsHumansAged6S-LEUCOVORINAged 80 and overCisplatinChemotherapybusiness.industryCombination chemotherapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensINFUSIONAL FLUOROURACILRANDOMIZED-TRIALOxaliplatinOxaliplatinSurvival RateRegimenOncologyFluorouracilINTENSIVE WEEKLY CHEMOTHERAPYETOPOSIDEFemaleFluorouracilbusinessResearch Articlemedicine.drug
researchProduct